Elucidation of Antiviral and Antioxidant Potential of C-Phycocyanin against HIV-1 Infection through In Silico and In Vitro Approaches

Antiretroviral therapy is the single existing therapy for patients infected with HIV; however, it has drawbacks in terms of toxicity and resistance. Thus, there is a continuous need to explore safe and efficacious anti-retroviral agents. C-Phycocyanin (C-PC) is a phycobiliprotein, which has been known for various biological properties; however, its effect on HIV-1 replication needs revelation. This study aimed to identify the inhibitory effects of C-PC on HIV-1 using in vitro and in silico approaches and to assess its role in the generation of mitochondrial reactive oxygen species (ROS) during HIV-1 infection. In vitro anti-HIV-1 activity of C-PC was assessed on TZM-bl cells through luciferase gene assay against four different clades of HIV-1 strains in a dose-dependent manner. Results were confirmed in PBMCs, using the HIV-1 p24 antigen assay. Strong associations between C-PC and HIV-1 proteins were observed through in silico molecular simulation-based interactions, and the in vitro mechanistic study confirmed its target by inhibition of reverse transcriptase and protease enzymes. Additionally, the generation of mitochondrial ROS was detected by the MitoSOX and DCF-DA probe through confocal microscopy. Furthermore, our results confirmed that C-PC treatment notably subdued the fluorescence in the presence of the virus, thus reduction of ROS and the activation of caspase-3/7 in HIV-1-infected cells. Overall, our study suggests C-PC as a potent and broad in vitro antiviral and antioxidant agent against HIV-1 infection.


Introduction
Current antiretroviral drugs for HIV-1 afford long-term and sustainable treatment options, allowing HIV-infected individuals to survive for many years. However, even fully suppressive antiretroviral therapy (ART) does not clear HIV-1 from the host and cessation of ART often leads to viral rebound [1]. Suppression of latent HIV-1 reservoirs requires life-long ART and that can be associated with serious complications, including cardiovascular and renal failure, peripheral neuropathy, and neurologic disease. Chronic antiretroviral drug treatment also promotes acquired drug resistance, leading to decreased ART efficacy and the potential spread of drug-resistant viruses [2]. Recent estimates report 1.5 million new HIV infections worldwide, totaling up to 37.7 million people living with HIV (UN-AIDS 2021). Controlling the spread of HIV infection with efficient management is therefore considered a top priority. These observations underscore the need for novel strategies to suppress HIV-1 replication and eliminate persistent viral reservoirs to achieve a functional cure.

Cytotoxicity Assay by MTT
The cytotoxicity of the C-Phycocyanin to TZM-bl cells and activated PBMCs was determined using the MTT assay (Sigma-Aldrich, St. Louis, MO, USA) as described previously [28]. Briefly, double dilutions of C-PC working stock (2 mg/mL) were prepared and added onto 1 × 10 4 adherent TZM-bl cells/well seeded in 96-well plates kept for overnight incubation under 5% CO 2 at 37 • C. After 48 h post-treatment, the cell viability was determined using 20µL (5 mg/mL) MTT reagent. Similarly, the activated PBMCs were treated with various concentrations of the pure protein and incubated for 5 days with 5% CO 2 at 37 • C incubator. Subsequently, the cell viability was determined using the MTT reagent as described above. After the final incubation, the optical density (OD) value was recorded at 550 nm and 630 nm using a multimode plate reader. The CC 50 values were obtained at the concentration where 50% of the cells remain viable in the presence of C-PC.

Cell Associated Anti-HIV-1 Assay
Based on the cell viability assay, a range of non-cytotoxic concentrations of the C-PC protein were selected and the anti-HIV-1 activity was evaluated. In a 96-well plate, the TZM-bl cells (1 × 10 4 cells/well) were first infected with different HIV-1 strains (subtype A-D) for 2 h at 37 • C in a 5% CO 2 atmosphere before exposing the infected cells to the serial dilutions of C-PC in duplicate (0.500-0.031 mg/mL). At 48 hpi, the luciferase activity was measured using the Britelite plus reagent (Perkin Elmer, Waltham, MA, USA). A reverse transcriptase inhibitor, azidothymidine or AZT, was taken as a positive control compound with anti-HIV-1 activity in the experiment.

HIV-1 p24 Antigen Capture Assay
The PBMCs were seeded in 96-well plates (0.2 × 10 4 cells/well) and infected with HIV-1 VB051 (40 TCID 50 ). This was followed by the addition of non-toxic concentrations of C-PC (0.5-0.195 mg/mL). After incubation for 5 days at 37 • C in a 5% CO 2 incubator, the virus supernatant was analyzed for the presence of HIV-1 p24 antigen through ELISA following the manufacturer's instruction (Abcam, Cambridge, UK). The absorbance was measured at a wavelength of 450 nm in an ELISA plate reader (BioRad, Hercules, CA, USA) and 50% inhibition concentration or IC 50 values were calculated based on the positive control provided in the kit.

HIV-1 Reverse Transcriptase Activity Assay
The inhibitory action of C-PC on HIV-1-RT was assessed using a commercially available kit (Roche, Mannheim, Germany). Briefly, dilutions of the C-PC were incubated with the HIV-1 RTase in addition to a template nucleotide mixture for 1 h. Consequently, the mixture was transferred to the microwell plates coated with streptavidin and followed by incubation for 1 h to bind with biotin, which is a DIG-labeled template primer complexed to the streptavidin-coated plate. The enzyme HRP conjugate was added to the above plate and followed by 1 h incubation. After the addition of the substrate, the color responses were measured at wavelengths 405 nm and 490 nm as a reference wavelength using BioRad reader PR4100. The IC 50 values were determined by non-linear regression curves. A known reverse transcriptase inhibitor nevirapine (NVP) was used as positive control.

HIV-1 Protease Assay
The inhibition of the HIV-1 protease enzyme by C-PC was examined using a commercially available kit following the manufacturer's instructions (Sigma-Aldrich, St. Louis, MO, USA). A known protease inhibitor Ritonavir was used as positive control.

Detection of Intracellular Reactive Oxygen Species (ROS)
To quantify the formation of ROS in TZM-bl cells, the MitoSOX molecular probe was used and the assay was performed as described earlier [29]. Briefly, TZM-bl were seeded into 96-well plates at a density of 1 × 10 4 cells per well in a volume of 100µL complete medium. After overnight incubation, cells were infected with the virus and treated with C-PC at different concentrations (0.500-0.031 mg/mL), and the assay was performed at 24 hpi. Initially, the infected cells were treated with 10µM MitoSOX at 37 • C in 5% CO 2 incubator. At 30 min post-incubation, the fluorescence intensity was measured at an excitation wavelength of 485 nm and an emission wavelength of 528 nm using a microplate reader (Perkin Elmer, Waltham, MA, USA).

Confocal Microscopy
A MitoSOX red molecular probe was used to identify the intracellular ROS production as superoxide (O 2 •− ) using confocal microscopy as described earlier [30]. Briefly, the TZM-bl cells were seeded onto the glass coverslips in a 6-well plate and after treatment for 24 h, the cells were incubated for 30 min with MitoSOX (10 µM) in the dark atmosphere. Subsequently, after washing with PBS, the cells were fixed with 3.7% paraformaldehyde and visualized under the laser-scanning confocal microscope (Nikon, Tokyo, Japan). Known ROS generators, 0.1 mM Xanthine + 0.01 U Xanthine oxidase were used as the positive control. 100U Cu-Zn SOD was also used as an inhibitor of ROS.

Screening of Caspase Activity
The Caspase-Glo 3/7 Assay (Promega, WI, USA) was used for the detection of in vitro caspase activity in the HIV-1-infected C-PC treated cells. The caspase-3/7 reagent contains the DEVD, a tetrapeptide aminoluciferin substrate, known for the detection of caspase-3/7 and luciferase activity. The addition of Caspase-Glo 3/7 directly onto the cells results in cell lysis followed by the caspase cleavage by the DEVD substrate, hence luminescence generation. The quantity of luminescence in the readout is relative to the amount of caspase activity present in the cells.

Assessment of Cell Death through FACS
The Annexin V-FITC conforming signal delivers a precise sensitive technique for detecting cellular apoptosis, whereas propidium iodide (PI) is used to detect necrotic or late apoptotic cells, categorized by the loss of the plasma and/or nuclear membranes integrity. Hence, cellular apoptosis was detected in the HIV-1-infected C-PC treated cells stained with Annexin V-FITC/PI through flow cytometry analysis. The Annexin V-FITC binding was recorded by the FL-1 signal detector, while the PI staining through the emission of FL-2 signal detector using BD FACS Vantage Analyzer (Becton-Dickinson, NJ, USA). A total of 10,000 events were acquired for the determination of fluorescence intensity and the Cell Quest software was used for the data analysis. Camptothecin (15 µm) was taken as a positive control for the FACS analysis.

Results
The present study aimed to evaluate the anti-HIV-1 and antioxidant activity of the major phycobiliprotein present in many marine cyanobacteria or some blue-green algae, known as C-Phycocyanin or C-PC, against the multiple subtypes of HIV-1 for anti-retroviral drug screening.

Cytotoxicity of C-Phycocyanin
The C-PC was screened to assess its effect on the viability of TZM-bl cells and PBMCs by MTT-based quantitative and colorimetric assay. The dose-dependent effect of C-PC (2.0-0.0312 mg/mL) was represented by the concentrations against the percentage of cell viability ( Figure 1A,B). The comparative cell viability between TZM-bl and PBMCs was depicted as almost analogous ( Figure 1C). The concentration that allows 50% viability of the cells was represented as CC 50 value found to be ≥0.986 and ≥0.872 mg/mL for TZM-bl and PBMC, respectively ( Figure 1D). The data showed that C-PC was safe and non-toxic to the cells in a range of 0.5000-0.3125 mg/mL for treatment, and was used in subsequent studies.

Anti-Viral Activity of C-Phycocyanin against HIV-1
We examined the antiviral activity of C-Phycocyanin via luciferase gene assay in TZM-bl cells. In the cell-based assays, TZM-bl cells were infected with four different subtypes of HIV-1 strains, individually, prior to the addition of different concentrations of C-Phycocyanin and incubated for 48 h before the termination of the assay. Treatment of C-PC at different concentrations (0.3125-0.500 mg/mL) led to comparable dose-dependent inhibition of HIV-1 92/RW/008 (subtype A), HIV-1 Ada5 (subtype B), HIV-1 VB051 (subtype C) and HIV-1 UG070 (subtype D) virus strains (Figure 2A). The 50% inhibition concentration or the IC 50 values were determined as 0.0846 mg/mL, 0.0817 mg/mL, 0.1603 mg/mL, and 0.1740 mg/mL for HIV-1 92/RW/008 , HIV-1 Ada5 , HIV-1 UG070 , and HIV-1 VB051 , respectively ( Figure 2B). Consequently, the anti-HIV-1 activity of C-PC was further confirmed in the PBMCs using the primary isolate HIV-1 VB051 , and a comparable pattern of dose-dependent inhibition of HIV-1 p24 antigen was determined ( Figure 2C). The IC 50 value detected for C-PC in PBMC was 0.090 mg/mL ( Figure 2D). Even the 80% inhibition of HIV-1 infection was observed at the non-toxic concentration of 0.3566 mg/mL of C-PC as recorded by the IC 80 value ( Figure 2D). Together, these results demonstrated that C-PC is capable of inhibiting viral replication against a broad range of HIV-1 clades.

Interactions of C-PC and HIV-1 Reverse Transcriptase
Computational studies were used to understand C-PC and HIV-1RT protein-protein interaction by performing Molecular Docking Simulation using the HADDOCK4.2 server. The molecular interactions were analyzed by measuring distances between protein residues, analyzing hydrogen bond and Van der Waals interactions, and binding energies, as shown in Table 1. Briefly, a hydrogen bond was defined as having a donor-hydrogen acceptor angle of more than 120 • and a distance between the donor and acceptor of <3.5 Å.  The p66 polymerase in HIV-1RT has a right-handed structural organization that contains finger subdomain residues (1-84, & 120-150), palm subdomain residues (85-119, and 151-243), and thumb subdomain residues (244-322), and liking subdomain residues (323-427) such as other polymerases. The polymerase active site residues (Asp110, Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg 2+ ) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3 end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 Antioxidants 2022, 11, 1942 8 of 19 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. The p66 polymerase in HIV-1RT has a right-handed structural organization that contains finger subdomain residues (1-84, & 120-150), palm subdomain residues (85-119, and 151-243), and thumb subdomain residues (244-322), and liking subdomain residues (323-427) such as other polymerases. The polymerase active site residues (Asp110, Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. The p66 polymerase in HIV-1RT has a right-handed structural organization that contains finger subdomain residues (1-84, & 120-150), palm subdomain residues (85-119, and 151-243), and thumb subdomain residues (244-322), and liking subdomain residues (323-427) such as other polymerases. The polymerase active site residues (Asp110, Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. The p66 polymerase in HIV-1RT has a right-handed structural organization that contains finger subdomain residues (1-84, & 120-150), palm subdomain residues (85-119, and 151-243), and thumb subdomain residues (244-322), and liking subdomain residues (323-427) such as other polymerases. The polymerase active site residues (Asp110, Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. (323-427) such as other polymerases. The polymerase active site residues (Asp110, Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. (323-427) such as other polymerases. The polymerase active site residues (Asp110, Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. The S-value obtained for C-PC and HIV-1RT interaction using MOE docking with a best score of −80.38 with the RMSD value at 1.105. The other scores obtained with reiteration are as given in Table S1. Amino acid Met69A of C-PC was found to have hydrophobic interaction with Met230 of HIV-1RT with a distance of 3.591Å while Asp77A of C-PC was shown to have ionic interaction with Lys259 of 4.456Å. Furthermore, Gln70A and Thr21B of C-PC were found to have contact interaction with Gly262 and Arg448 residues of HIV-1RT (Tables S2 and S3, Figure S1).

Inhibitory Effect of C-Phycocyanin on HIV-1 Reverse Transcriptase
The HIV-1 RT is a unique and key enzyme that controls HIV-1 replication in the infected cells.
In this study, we found that the increasing concentrations of C-PC (0.015-0.500 mg/mL) inhibited the activity of HIV-1_RT in agreement with the in silico studies. Whereas the maximum inhibition of HIV-1 RTase (89.8%) was observed at the highest concentration of 0.500 mg/mL ( Figure 4A), the IC 50 value was found to be 0.025 mg/mL for C-PC protein ( Figure 4B). The results were compared with the known RTase inhibitor NVP, at a concentration of 2µM for 97% inhibition of the viral protein, with the IC 50 value found to be at 0.0018 mg/mL ( Figure 4B).

C-Phycocyanin Suppress the HIV-1 Protease Activity
HIV-1 protease is an important enzyme that plays an imperative role in the maturation of the virus and consequently in the infection of new cells. It is the key enzyme of the HIV-1 life cycle acting at the post-entry level. As indicated in Table 3, the molecular interactions were examined by measuring residue contacts between HIV-1PR and C-PC residues, examining hydrogen bond and Van der Waals interactions, and examining binding energies. Briefly, a hydrogen bond was described as having a distance of <3.5 Å between the donor and acceptor with a donor-hydrogen acceptor angle >120 • . The in silico analysis of C-Phycocyanin and HIV-1 PR association predicted ample evidence of inhibitory interactions ( Figure 5, Table 4). The proteolytic active site formed by amino acids Asp25, Asp29 and Asp30 in HIV-1PR is completely occupied by C-PC through hydrogen bonds, therefore inhibiting proteolysis. Additionally, C-PC also renders favorable conformational changes in the flexible glycine-rich 'flap region (residues 44-57)' consisting of two β-hairpins that covers the active cleft in HIV-1PR.  pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. 14 subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along  with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. Asp185, and Asp186) are found in the β6-β10-β9 sheet of the palm subdomain, and all these domains define a primer binding cleft [32]. It is carboxylated in the p66 palm subdomain, which interacts with two magnesium divalent ions (Mg2+) for catalysis and, as a result, aids in the addition of nucleotides to the developing primer strand known as "primer grip" for proper positioning of the 3′ end [33]. Tyr-Met-Asp-Asp is present in the subunits p66 and p51, but the "thumb's knuckle" is close to Trp239 (positions β14 and β15) and Val317 (position β15). The β5-β6 of the loop, β6, β9-10, β12-β13 of the hairpin, β15 of the p66, and β7-β8 connecting loop of the p51 make up the majority of the binding pocket for non-nucleosides for inhibition. Gly231, Trp266, Tyr188, and Trp229 side chain residues are also present in this pocket [32]. The protein-protein molecular modeling and simulation studies revealed molecular alignment of C-PC with HIV-1RT by forming three hydrogen bonds with active residues Leu279 (3.03 Å), Lys281 (3.03 Å) and Lys281 (2.55 Å) ( Table 2) and 09 hydrophobic interactions with Tyr181, Tyr188 and Tyr318 along with other sub-site catalytic residues Pro95, Leu100, Lys101, Lys103, Val106, Glu138, Val179, Ile180, Gly190, Trp229, His235, and Tyr310 in HIV-1RT (Table 2 and Figure 3). The active site catalytic residues, motif, and other noteworthy residues mentioned above located in the active pocket of HIV-1RT are occupied by C-PC, therefore playing a role in the inhibition of HIV-1-RT activity [34]. C-PC has made a noteworthy molecular interaction with HIV-1PR by forming total 08 hydrogen bonds with residues Asn25A, Asn25B, Gly27B, Asp29B, Asp30A, Asp30B and other Van der Waals interactions present in the active binding site of chain A and chain B (Table 4). Furthermore, the active binding site of HIV-1PR was lined up with the following active residues from chains A and B: Leu23, Thr26, Gly27, Ala28, Thr31, Val32, Lys45, Met46, Ile47, Gly48, Gly49, Ile50, Gly51, Phe53, Leu76, Thr80, Pro81, Val82, Asn83, and Ile84, where C-PC considerably made contacts ( Figure 5 and Table 4). Similar types of interactions in active binding sites were also predicted using MOE tools (Table S1-S3 and Figure S2).
The structural conformational changes rendered by C-PC in HIV-1PR structure through hydrogen bonds and Van der Waals interactions, which therefore led to inhibition of HIV-1PR activity. The potency of C-PC was examined against HIV-1 PR, in a dose-dependent manner, through in vitro assay ( Figure 6). A maximum of 92.88% inhibition was observed at the highest C-PC concentration of 0.500 mg/mL ( Figure 6). Furthermore, the C-PC showed the possession of a moderate in vitro inhibitory potency against HIV-1 PR with an IC 50 value of 0.090 mg/mL. The results were validated with a known HIV-1 protease inhibitor Ritonavir (RTV) as a positive control with the IC 50 value of 0.000005 mg/mL (data not shown).

In Silico Interactions of C-PC with Other Crucial HIV-1 Proteins and Viral Co-Receptor
As described in the methodology section, the interactions between C-PC (1HA7) and other HIV-1 proteins along with their receptors CXCR4 and CCR5 were also assessed using MOE software tools. A similar pattern of interaction and protocol of study was followed for these complexes vizHA7-1QS4 (integrase), 1HA7-37J0 (GP120), 1H7-3ODU (CxCR4) and 1HA7-4MBS (CCR5). The S-value −69.0002 and −79.1704 for HIV-1-INT and GP120, respectively, were found to be in noble interaction conformation with C-PC (Table S1). Glu109A of C-PC interacts with Arg199 of HIV-1-INT (1QS4) via a hydrophobic interaction with the distance of 3.375 Å, while the Met1B interacts with Asp202 with an ionic interaction. Only two interactions and a resulting S-value of −69.0002 pointed towards the weak interaction between C-PC and HIV-1-INT proteins. On the other hand, six various types of interactions (polar, hydrophobic, ionic, etc.) make C-PC and glycoprotein GP120 of HIV-1 (3J70) complex conformationally and energetically stable and profound. Polar interaction between Ala113A and Gln203 makes this protein -protein complex potently stable with a good energetic S-value of −79.1704 (Tables S2 and S3, Figures S3 and S4).
In the case of C-PC and CxCR4 complex, Glu7A, Gly114A, Ser14A, Asp109B, Glu117B, and Leu120B of C-PC protein, respectively, interacts with Lys1085, Arg1119, Leu1079, Arg1096, His140, and again His140 of CxCR4 protein. The S-value of −78.2342 for this complex suggests strong interaction of both the partner proteins. In the case of CCR5, the complex 1HA7-4MBS has shown the best S-value of −81.7884 with 1.2111 RMSD value and multiple interacting amino acids with ionic, hydrophobic and Van der Waals type of interactions. CxCR4 and CCR5 being the host receptors for viral entry, these also hold a significance to further verify in experimental settings (Tables S1-S3, Figures S5 and S6).
Overall, the protein-protein interaction profile of C-PC with HIV-1-GP120, co-receptor CxCR4 and CCR5 shows stronger interactions in comparison C-PC and HIV-1-INT complex.

ROS Scavenging Activity of C-Phycocyanin in HIV-1 Infected Cells
To determine the antioxidant activity of C-PC in HIV-1-infected TZM-bl cells, ROS level was measured using the MitoSOX fluorescent probe. Confocal microscopy results indicated higher levels of mitochondrial ROS content in the HIV-1-infected group compared to the mock-infected cells ( Figure 7A). The C-PC treated HIV-1-infected cells showed lower fluorescence intensity ( Figure 7A), which was further confirmed through the quantification analysis. The dose-dependent (0.500-0.031 mg/mL) treatment of C-PC significantly decreased the level of intracellular ROS up to 3.87-fold in HIV-1-infected cells suggesting that C-PC ameliorated the ROS production ( Figure 7B). These results were further supported by the confocal microscopy using fluorescent-based molecular probe, 2,7 Dichlorodihydroflurescin diacetate (H2DCF-DA), where ROS elevation was detected in HIV-1-infected cells compared to mock infection, and C-PC treatment subsequently resulted in a reduction in intracellular ROS production ( Figure S7).  Figure 7C).
Furthermore, the effect of C-PC in HIV-1 induced cell death was investigated by annexin V/PI staining through FACS-based analysis. Results showed that cell death during HIV-1 infection was mainly due to necrosis (Q1) and apoptosis (Q2 and Q4). However, treatment of C-PC notably reduced both the necrosis and apoptotic population in HIV-1infected cells (Figure 8). In HIV-1-infected population at 24 hpi, the cells were scattered in the different phases of cell death recorded as 2.0% of early apoptosis (Q4), 10.7% of late apoptosis (Q2), and 53.1% of necrosis (Q1); however, treatment of IC 50 concentration (0.1740 mg/mL) of C-PC in HIV-1-infected TZM-bl cells considerably suppressed the distribution of dead cells by 60% in early apoptosis (0.8% in Q4), 69% in late apoptosis (3.3% in Q2), and 28% in necrosis (38.3% in Q1) phases ( Figure 8). Camptothecin (15µm) was used as positive control of cell death due to apoptosis and necrosis.

Discussion
The limitations of antiretroviral medications in terms of resistance and toxicity becoming the greatest challenge for HIV-1 patients under ART; hence, the quest for new and powerful natural inhibitors is the only alternative solution against these major limitations. Therefore, in this present study, we examined the effect of such a natural inhibitor C-Phycocyanin or C-PC on HIV-1 extenuation. The results from our study could be briefed as C-PC significantly reduced viral infection and replication in wide clades of HIV-1 viruses (Figure 2). It also inhibited the important viral proteins, HIV-1 reverse transcriptase and protease, which is inferred from in silico molecular interactions (Figures 3 and 5), as well as in vitro kit-based enzymatic validations (Figures 4 and 6). Additionally, it has ROS scavenging activity indicating its potential application as an antioxidant agent (Figure 7), thus combined antioxidant effect and antiviral efficacy of C-PC may represent a promising therapeutic approach.
C-Phycocyanin, a phycobiliprotein that is present in some blue-green algae and marine cyanobacteria is known to exhibit a broad range of pharmacological actions [6,35,36]. Viral inhibitors produced from cyanobacteria and microalgae were reported to have antiviral potential throughout pathogenesis [37]. Through in vitro studies the anti-viral potential of Spirulina extract and its components have been mentioned previously, including the influenza virus, human immunodeficiency virus type 1 (HIV-1), herpes simplex virus type 1 (HSV-1), human cytomegalovirus, measles, and mumps virus infections [38][39][40][41][42]. It has also been reported that the extracts of Spirulina is completely safe and well tolerated through in vitro and in vivo studies [38]. Likewise, our findings support the previous studies by indicating that C-PC has anti-retroviral potential against various clades of HIV-1, and is safe up to 0.5 mg/mL to the cells, as confirmed by the cell viability assay.
Herein we focused on the inhibitory effects of C-PC protein against the HIV-1 reverse transcriptase and protease enzymes. The HIV-1-RT is a unique and essential enzyme that regulates the viral replication in the infected cells. Moreover, the HIV-1-RT performs a variety of tasks, including DNA polymerase and RNase H functions; while RNase H is responsible for the breaking down of viral RNA, DNA polymerase creates the cDNA from the viral RNA template, finally, contributing toward the HIV-1 replication cycle [43]. On the other hand, HIV-1-PR is another important enzyme that plays a crucial role in virus maturation process and consequently in the infection of new cells, by cleaving the polyproteins into functional viral proteins [44]. Hence, the HIV-1-PR is the key enzyme of the HIV-1 life cycle acting at the post-entry level. Due to their importance in viral life cycle, the HIV-1-RT and -PR are most often used for effective drug targets in HIV treatment [17]. The inhibitory effects of microalgae and cyanobacteria extracts on various other viral replications and their enzymatic activities have been elaborately discussed [45][46][47][48][49][50][51]. Our results also showed that C-PC served as potential HIV-1 inhibitors, both for HIV-1-RT as well as -PR. While the in silico analyses by computer-aid molecular docking predicted associations of C-PC with the HIV-1-RT and -PR, and potential interferences in their active sites to block the viral replication, the in vitro assays confirmed significant inhibition of both the HIV-1 enzyme activities in the presence of C-PC (0.05 mg/mL). The effect of C-PC on inhibition of HIV-1-RT and -PR was significant as compared to the effect of known chemical inhibitors NVP (RT) and RTV (PR), respectively. This study is the first to report the anti-HIV-1 activities of the phycobiliprotein C-PC against HIV-1-RT and -PR through in silico and in vitro approaches.
Several studies have revealed that the viral interactions with mitochondrial membranes and other components connected to mitochondria produce greater amounts of reactive oxygen species (ROS) [52]. These virus-induced mitochondrial ROS (mtROS) ultimately promotes viral replication through modulation of host pathways and covalent changes in the viral components, finally leads toward mtROS-induced apoptosis (intrinsic apoptosis), which is an important viral strategy for optimal intracellular viral replication and timely release of viral progeny [52]. The role of ROS in HIV pathogenesis was also speculated earlier [53,54]. Previous studies on phycobiliproteins have been reported for their antioxidant effects upon several pathogens and/or across the multiple cell types [55][56][57][58][59]. In our study, ROS generation was observed after 24 h of post-HIV-1 infection using molecular probe MitoSOX TM and DCF-DA. HIV-1-infected cells showed increased fluorescence, while C-PC was found to reduce ROS generation in HIV-1-infected cells competently, ascertaining the role of C-PC protein as potent antioxidant. Hence, in agreement with the previous studies, C-PC also exhibited antioxidant effects, indicating its potential application as therapeutic agents against HIV-1 infection.
The loss of immune cells, notably CD4+ T-cells, is the defining feature of HIV-1 infection. Prior study showed that the HIV-1 envelope glycoproteins were responsible for the decrease of CD4+ T-cells, which resulted from oxidative stress accumulation and cell death [60]. According to these findings, managing the HIV-1 viral load and maintaining a healthy level of antioxidants are crucial components of HIV-1 patient care. Treatment with the antioxidant N-acetylcysteine in HIV-1-infected patients was able to increase glutathione levels and overall antioxidant status while lowering lipid peroxidation [61]. As ROS are short-lived and highly reactive molecules, high doses of ROS activate the mitochondriaand caspase-dependent apoptotic cell death signaling pathways. Caspase-3 acts as a point of convergence for both mitochondria-dependent and -independent processes in cells undergoing apoptotic cell death in response to oxidative stress [62,63]. Caspases, which are the members of the family of cysteine proteases, causes programmed cell death upon activation, and also found triggered by HIV-1 envelope proteins [64]. Our results revealed that HIV-1 virus-infected cells are responsible for the activation caspase-3/7, which is in line with the previous findings. However, C-PC supplementation in HIV-1-infected cells not only prevented the production of ROS but also decreased the activation of caspases-3/7 and the number of apoptosis cells, asserting its effect on cell death by reducing intracellular ROS.
Overall, this study identified the C-PC as a potential active substance that could obstruct HIV-1-RT and PR activities, therefore, offering an intriguing concept for developing natural anti-HIV drugs. However, it is plausible that additional anti-viral mechanisms could also be involved in C-PC mediated extenuation of HIV-1 replication, thus using the in silico analysis, ancillary molecular interactions between C-PC and other crucial viral proteins, including the glycoprotein GP-120, HIV-1 integrase and host targets like co-receptors CxCR4 and CCR5 was also investigated (Supplementary data). Although these interactions were not validated by the in vitro analysis, results from the in silico studies have indicated that C-PC also interacts with these viral proteins and co-receptors with appreciable binding interactions with significant bond energies between the amino acids of the associating proteins. Furthermore, undoubtedly the validation of anti-HIV-1 effects of the C-PC should be studied further. This will provide new insights into the possibility of using these proteins as adjunct therapy to restrict the spread of this deleterious virus.

Conclusions
In summary, we identified the negative regulatory effects of C-Phycocyanin on HIV-1 infection through in silico molecular associations with the viral proteins that has been further validated through in vitro mechanistic assays. The reverse transcriptase, which is the crucial enzyme for HIV-1 replication and the protease that plays the significant function in virus maturation and viral transmission, have been significantly suppressed the presence of C-PC. Moreover, the compound also exhibited ROS scavenging activity in HIV-1-infected cells, confirming its antioxidant potential and inhibitory effects on virus life cycle. Overall, our findings imply the potential antiretroviral property of C-Phycocyanin and might be an imperative asset in the field of anti-HIV medicine.
Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/antiox11101942/s1. This section contains the supplemental text related to the detailed methods used involving the MOE software-based molecular docking and interaction studies. This section also contains all supplementary tables (Table S1-S3) and figures ( Figure S1-S7), which are cited in the main text.

Data Availability Statement:
The data presented in this study are available on request from the corresponding author.